DB&C Advisors’s Pfizer PFE Stock Holding History

DB&C Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$753K	Buy	31,267 +185	+0.6%	+$4.84K	0.82%	35
2026 Q1	$873K	Sell	31,082 -6,100	-16%	-$162K	1.13%	28
2025 Q4	$926K	Buy	+37,182	New	+$938K	1.16%	25

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DB&C Advisors's PFE Position: Q2 2026 in Review

DB&C Advisors increased its Pfizer (PFE) stake by 0.6% in Q2 2026, buying an estimated $4.84K and bringing the position to 31,267 shares worth $753K. The position accounts for 0.82% of the portfolio, ranked #35.

DB&C Advisors first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $926K in Q4 2025. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

DB&C Advisors held 31,267 shares of Pfizer worth $753K as of Q2 2026.
DB&C Advisors bought 185 Pfizer shares in Q2 2026, an estimated $4.84K.
Pfizer made up 0.82% of DB&C Advisors's portfolio in Q2 2026, its #35 holding.
DB&C Advisors first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
DB&C Advisors's Pfizer position peaked at $926K in Q4 2025.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on DB&C Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.